NeuroSense Therapeutics Ltd.
$0.71
▲
9.21%
2026-04-21 08:28:01
www.neurosense-tx.com
NCM: NRSN
Explore NeuroSense Therapeutics Ltd. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$25.1 M
Current Price
$0.71
52W High / Low
$2.6 / $0.63
Stock P/E
—
Book Value
$-0.05
Dividend Yield
—
ROCE
-383.35%
ROE
-21.75%
Face Value
—
EPS
$-0.44
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
17
Beta
1.68
Debt / Equity
0.03
Current Ratio
0.31
Quick Ratio
0.31
Forward P/E
-1.39
Price / Sales
—
Enterprise Value
$24.75 M
EV / EBITDA
-2.24
EV / Revenue
—
Rating
Strong Buy
Target Price
$8.38
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Aligos Therapeutics, Inc. | $6.51 | — | $41.33 M | — | -130.74% | -1.97% | $13.69 / $4.2 | $8.67 |
| 2. | Enlivex Ltd. | $0.88 | — | $207.92 M | — | -0.65% | 1.26% | $2.1 / $0.66 | $8.15 |
| 3. | Equillium, Inc. | $2.01 | — | $127.09 M | — | -81.63% | -94% | $2.7 / $0.27 | $0.47 |
| 4. | Jupiter Neurosciences, Inc. | $0.46 | — | $15.86 M | — | -73.72% | -7.39% | $3.33 / $0.31 | $0 |
| 5. | CytomX Therapeutics, Inc. | $4.89 | — | $1.06 B | — | -21.31% | -35.25% | $8.21 / $0.61 | $0.58 |
| 6. | Genprex, Inc. | $1.16 | — | $10.45 M | — | -194.32% | -3.39% | $55 / $1.15 | $3.78 |
| 7. | Oculis Holding AG | $28.61 | — | $1.64 B | — | -41% | -73.45% | $30.68 / $16 | $4.24 |
Quarterly Results
Figures shown in M / B
| Q4 2024 | Q3 2024 | |
|---|---|---|
| Sales | 0 M | 0 M |
| Operating Profit | -1.77 M | -2.11 M |
| Net Profit | -1.8 M | -2.15 M |
| EPS in Rs | -0.05 | -0.06 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -11.09 M | -9.9 M | -12.05 M | -10.55 M |
| Net Profit | -11.12 M | -10.21 M | -10.11 M | -10.49 M |
| EPS in Rs | -0.33 | -0.31 | -0.3 | -0.31 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1.03 M | 4.58 M | 3.19 M | 7.71 M |
| Total Liabilities | 2.59 M | 1.99 M | 4.94 M | 2.09 M |
| Equity | -1.56 M | 2.58 M | -1.76 M | 5.62 M |
| Current Assets | 0.78 M | 4.4 M | 2.92 M | 7.38 M |
| Current Liabilities | 2.52 M | 1.99 M | 3.46 M | 1.73 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -7.67 M | -10.13 M | -8.35 M | -7.62 M |
| Investing CF | -0.01 M | 0 M | 3.47 M | -3.59 M |
| Financing CF | 4.43 M | 10.91 M | 3.98 M | 3.77 M |
| Free CF | -7.68 M | -10.14 M | -8.38 M | -7.69 M |
| Capex | -0.01 M | -0 M | -0.03 M | -0.07 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -1.02% | 3.67% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.